Abstract:Diabetes mellitus is a complex disease characterised by chronic hyperglycaemia responsible for complications affecting the kidneys, eyes, peripheral nerves and micro- and macrovascular systems. Von Willebrand factor (vWf), a multimeric glycoprotein mainly synthesised by endothelial cells, is involved in platelet adhesion and aggregation and acts as the carrier of coagulation factor VIII in plasma. Increased levels of vWf, reflecting activation of or damage to endothelial cells, have been described in association with atherosclerosis and diabetes. vWf appears to be a predictive marker of diabetic nephropathy and neuropathy, although not of retinopathy, which suggests that endothelial dysfunction precedes the onset of diabetic microangiopathy. This dysfunction could be especially involved in the pathogenesis of renal abnormalities of diabetes. vWf is not a predictive marker of macroangiopathy when diabetes is associated with atherosclerotic risk factors. In the presence of chronic diabetic complications, vWf levels are not associated with any grade of retinopathy but increase with the severity of nephropathy and would appear to be a risk factor for macrovascular mortality in these patients. The endothelial dysfunction of diabetes can generate atherosclerotic lesions responsible for damage to the arterial wall, atheroma and formation of platelet microaggregates. Concomitant with high vWf levels, other possible mechanisms of endothelial damage include reduced synthesis or release of nitric oxide, hyperglycaemic pseudohypoxia and protein kinase-C activation, increased synthesis of proteins bearing advanced glycosylation end-products or transforming growth factor-beta (TGF-beta) activation of coagulation and inhibition of fibrinolysis. At present, it is not known whether high vWf levels are inherent to the physiopathology of diabetes, nor whether diabetes induces endothelial dysfunction through other pathways. However, since angiopathy resulting from endothelial dysfunction is the main cause of morbidity and mortality in diabetic patients, appropriate therapy is necessary to reduce these complications. Glycaemic control seems to be insufficient to normalise plasma vWf, whereas a decrease can be obtained by ingestion of diets rich in oleic acid or by treatment with statins. Inhibition of the binding of vWf to the GPlba receptor by synthetic peptides, aurin tricarboxylic acid or monoclonal antibodies has been proposed to prevent the thrombosis induced by high levels of plasma vWf. Thus, vWf probably represents an interesting target for the inhibition of thrombosis in diabetes.

Relationship Between Plasma Vwf-Cp Activity and Vascular Complications of Type 2 Diabetes Mellitus Patients

VEGF Levels in Plasma in Relation to Metabolic Control, Inflammation, and Microvascular Complications in Type-2 Diabetes A Cohort Study

Changes of Pulse Wave Velocity in Patients with Coronary Artery Disease Combined with Diabetes Mellitus

Plasma Levels of Von Willebrand Factor in Type 2 Diabetes Patients with and Without Cardiovascular Diseases: A Meta-Analysis.

Determination of Vasculopathy-Related Indexes in Patients with Type 2 Diabetes Mellitus and Its Clinical Significance

Measurements of NO, Vwf and DD in Patients with Type 2 Diabetes Mellitus and Theirs Clinical Significance

Relationship between circulating vascular cell adhesion molecule-1 and vascular complications in type 2 diabetes mellitus]

Effect of the complicated hypertension in type 2 diabetes mellitus patients on new-onset cardio-cerebro-vascular events in women population

Relationship between the type 2 diabetes mellitus patients serum Lp(a) levels and vas cular complications

Changes and significance of vascular endothelial injury markers in patients with diabetes mellitus and pulmonary thromboembolism

Changes and Clinical Implications of Plasma ANP,BNP and CNP Levels in Type 2 Diabetic Patients with Vascular Complications

Research of Relationship among D-dimer and Type 2 Diabetes and Macrovascular Compliations

Changes of Plasma Total Homocysteine in Type I Diabetic Patients Its Association with Diabetic Vascular Complications

The Relationship Between Changes of Plasma Fibrinolysis and Coagulation Parameters and Type 2 Diabetic Microangiopathy

Correlation of serum vaspin level to type 2 diabetes and diabetic microangiopathy

Von Willebrand factor in diabetic angiopathy

Clinical epidemiological analysis of type 2 diabetes patients with peripheral vascular disease

Changes of Von Willebrand Factor in Senile Patients with Type 2 Diabetes Mellitus and Its Relationship with Coronary Artery Disease

Clinical Significance of Measurement of Prethrombotic State in Patients with Type 2 Diabetes Mellitus

Analysis of relative factors on the prevalence of macrovascular complications and their risk factors in newly-diagnosed patients with type 2 diabetes mellitus

Clinical Study of the Risk Factors in Type-2 Diabetes Patients with Vascular Occlusive Disease